A Phase II Randomized Study of the Virologic and Immunologic Effects of Zidovudine Plus Lamivudine (3TC) Versus d4T Versus Zidovudine Plus d4T in HIV-Infected Patients With CD4 Cell Counts Between 300-600/mm3 and No Previous Nucleoside Experience

The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs

Sponsors

Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Source National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

To determine drug efficacy and safety in HIV-infected patients treated with zidovudine ( AZT ) versus stavudine ( d4T ) versus both drugs. Also, to compare short- and long-term changes in magnitude of HIV RNA over time.

Asymptomatic patients with CD4 counts over 300 cells/mm3 are more likely to tolerate any of the nucleoside analogs. d4T, with a favorable toxicity profile and demonstrated anti-HIV activity in previous studies, provides an additional therapeutic option.

Detailed Description

Asymptomatic patients with CD4 counts over 300 cells/mm3 are more likely to tolerate any of the nucleoside analogs. d4T, with a favorable toxicity profile and demonstrated anti-HIV activity in previous studies, provides an additional therapeutic option.

Patients are randomized to receive d4T alone, AZT alone, or both in combination for at least 12 weeks. After week 12, 3TC is added to the combination arm. Treatment continues for up to 48 weeks (was a total of 48 weeks, amended 3/26/96).

Overall Status Completed
Completion Date November 1997
Phase Phase 2
Study Type Interventional
Enrollment 105
Condition
Intervention

Intervention type: Drug

Intervention name: Lamivudine

Intervention type: Drug

Intervention name: Stavudine

Intervention type: Drug

Intervention name: Zidovudine

Eligibility

Criteria:

Inclusion Criteria

Concurrent Medication:

Required:

- TMP / SMX, aerosolized pentamidine, or dapsone for PCP prophylaxis.

Allowed:

- Atovaquone.

- IV pentamidine.

- TMP / SMX.

- Trimetrexate.

- Trimethoprim-dapsone.

- Clindamycin-primaquine.

- Topical antifungals.

- Clotrimazole.

- Ketoconazole.

- Fluconazole.

- Amphotericin B.

- Itraconazole.

- Rifabutin.

- Isoniazid.

- Pyrazinamide.

- Clofazimine.

- Clarithromycin.

- Azithromycin.

- Ethambutol.

- Amikacin.

- Ciprofloxacin.

- Ofloxacin.

- Pyrimethamine.

- Sulfadiazine.

- Clindamycin.

- Filgrastim ( G-CSF ).

- Up to 1000 mg/day acyclovir.

- Erythropoietin.

- Antibiotics.

- Antipyretics.

- Analgesics.

- Antiemetics.

- Rifampin.

Concurrent Treatment:

Allowed:

- Local radiation therapy.

Patients must have:

- HIV infection.

- CD4 count 300 - 600 cells/mm3.

- NO history of AIDS.

- NO active opportunistic infection.

- NO prior nucleoside therapy.

- Life expectancy at least 2 years.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

- Serious underlying medical condition other than HIV such that life expectancy is less than 2 years.

- Malignancy requiring systemic cytotoxic chemotherapy.

- Active grade 2 or worse peripheral neuropathy.

Concurrent Medication:

Excluded:

- Antiretrovirals other than study drugs.

- Systemic cytotoxic chemotherapy.

- Foscarnet.

Patients with the following prior conditions are excluded:

- Chronic diarrhea defined as three or more stools per day for 15 days, within 30 days prior to study entry.

- Unexplained temperature >= 38.5 C for any 7 days within 30 days prior to study entry.

- Active participation in other experimental therapy within 30 days prior to study entry.

Prior Medication:

Excluded:

- Prior nucleoside antiretrovirals of 1 week or longer duration.

- Any antiretroviral within 90 days prior to study entry.

- Non-nucleoside reverse transcriptase inhibitors and protease inhibitors within 30 days prior to study entry.

- Biologic response modifiers such as IL-2 and interferon within 30 days prior to study entry.

Gender: All

Minimum age: 12 Years

Maximum age: N/A

Healthy volunteers: No

Overall Official
Location
facility
Alabama Therapeutics CRS | Birmingham, Alabama, 35294, United States
Stanford CRS | Palo Alto, California, 94305, United States
Ucsd, Avrc Crs | San Diego, California, 92103, United States
Howard University Hosp., Div. of Infectious Diseases, ACTU | Washington, District of Columbia, 20059, United States
The Ponce de Leon Ctr. CRS | Atlanta, Georgia, United States
Johns Hopkins Adult AIDS CRS | Baltimore, Maryland, 21287, United States
St. Louis ConnectCare, Infectious Diseases Clinic | St Louis, Missouri, 63112, United States
Washington U CRS | St. Louis, Missouri, 63110, United States
Beth Israel Med. Ctr. (Mt. Sinai) | New York, New York, 10003, United States
NYU Med. Ctr., Dept. of Medicine | New York, New York, 10016, United States
Unc Aids Crs | Chapel Hill, North Carolina, 27599, United States
The Ohio State Univ. AIDS CRS | Columbus, Ohio, 43210, United States
Puerto Rico-AIDS CRS | San Juan, Puerto Rico
Location Countries

Puerto Rico

United States

Verification Date

May 2012

Responsible Party

Responsible party type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Study Design Info

Primary purpose: Treatment

Source: ClinicalTrials.gov